Bank of New York Mellon’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Bank of New York Mellon’s Portfolio VCNX Stock Details VCNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-85	Closed	-$54K	–	4486
2021 Q1	$54K	Buy	+85	New	+$54.6K	﹤0.01%	4249
2020 Q3	–	Sell	-76	Closed	-$57K	–	4160
2020 Q2	$57K	Hold	76	–	–	﹤0.01%	3970
2020 Q1	$64K	Sell	76 -3	-4%	-$3.4K	﹤0.01%	3934
2019 Q4	$80K	Hold	79	–	–	﹤0.01%	4049
2019 Q3	$119K	Hold	79	–	–	﹤0.01%	4000
2019 Q2	$91K	Hold	79	–	–	﹤0.01%	4042
2019 Q1	$87K	Sell	79 -2	-2%	-$1.92K	﹤0.01%	4024
2018 Q4	$62K	Hold	81	–	–	﹤0.01%	4034
2018 Q3	$124K	Buy	+81	New	+$167K	﹤0.01%	4004

Other funds holding VCNX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon's VCNX Position: Q2 2021 in Review

Bank of New York Mellon sold out of Vaccinex, Inc. Common Stock (VCNX) in Q2 2021, closing a stake of 85 shares — an estimated $54K sold.

Bank of New York Mellon first reported a position in VCNX in Q3 2018 and held it in 9 quarters. The position peaked at $124K in Q3 2018. 24 funds tracked by Wall St. Rank hold VCNX as of Q2 2021.

Bank of New York Mellon reported no remaining Vaccinex, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Bank of New York Mellon sold 85 Vaccinex, Inc. Common Stock shares in Q2 2021, an estimated $54K.
Bank of New York Mellon first reported a position in Vaccinex, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
Bank of New York Mellon's Vaccinex, Inc. Common Stock position peaked at $124K in Q3 2018.
24 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.